MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

UroGen Pharma Ltd

Cerrado

17.05 -4.48

Resumen

Variación precio

24h

Actual

Mínimo

16.66

Máximo

17.98

Métricas clave

By Trading Economics

Ingresos

-6.1M

-50M

Ventas

4M

24M

Margen de beneficios

-206.236

Empleados

253

EBITDA

-4.5M

-41M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+106.68% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-33M

885M

Apertura anterior

21.53

Cierre anterior

17.05

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

UroGen Pharma Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 jun 2025, 18:34 UTC

Principales Movimientos del Mercado

UroGen Pharma Shares Rise on FDA Approval of Bladder Cancer Drug

16 may 2025, 19:39 UTC

Principales Movimientos del Mercado

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

Comparación entre iguales

Cambio de precio

UroGen Pharma Ltd previsión

Precio Objetivo

By TipRanks

106.68% repunte

Estimación a 12 Meses

Media 36.83 USD  106.68%

Máximo 47 USD

Mínimo 31 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para UroGen Pharma Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

6

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

9.625 / 11.64Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Neutral Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de UroGen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
help-icon Live chat